These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 11689643

  • 1. A cyclic dodecapeptide-multiple-antigen peptide conjugate from the undecapeptidyl arch (from Arg(168) to Cys(178)) of extracellular loop 2 in CCR5 as a novel human immunodeficiency virus type 1 vaccine.
    Misumi S, Nakajima R, Takamune N, Shoji S.
    J Virol; 2001 Dec; 75(23):11614-20. PubMed ID: 11689643
    [Abstract] [Full Text] [Related]

  • 2. Evidence as a HIV-1 self-defense vaccine of cyclic chimeric dodecapeptide warped from undecapeptidyl arch of extracellular loop 2 in both CCR5 and CXCR4.
    Misumi S, Takamune N, Ido Y, Hayashi S, Endo M, Mukai R, Tachibana K, Umeda M, Shoji S.
    Biochem Biophys Res Commun; 2001 Aug 03; 285(5):1309-16. PubMed ID: 11478800
    [Abstract] [Full Text] [Related]

  • 3. A novel cyclic peptide immunization strategy for preventing HIV-1/AIDS infection and progression.
    Misumi S, Endo M, Mukai R, Tachibana K, Umeda M, Honda T, Takamune N, Shoji S.
    J Biol Chem; 2003 Aug 22; 278(34):32335-43. PubMed ID: 12771150
    [Abstract] [Full Text] [Related]

  • 4. Effects of immunization with CCR5-based cycloimmunogen on simian/HIVSF162P3 challenge.
    Misumi S, Nakayama D, Kusaba M, Iiboshi T, Mukai R, Tachibana K, Nakasone T, Umeda M, Shibata H, Endo M, Takamune N, Shoji S.
    J Immunol; 2006 Jan 01; 176(1):463-71. PubMed ID: 16365439
    [Abstract] [Full Text] [Related]

  • 5. Suppression of multiclade R5 and X4 human immunodeficiency virus type-1 infections by a coreceptor-based anti-HIV strategy.
    Nakayama D, Misumi S, Mukai R, Tachibana K, Umeda M, Shibata H, Takamune N, Shoji S.
    J Biochem; 2005 Nov 01; 138(5):571-82. PubMed ID: 16272569
    [Abstract] [Full Text] [Related]

  • 6. Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.
    Khurana S, Kennedy M, King LR, Golding H.
    J Virol; 2005 Jun 01; 79(11):6791-800. PubMed ID: 15890918
    [Abstract] [Full Text] [Related]

  • 7. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
    Baba M, Takashima K, Miyake H, Kanzaki N, Teshima K, Wang X, Shiraishi M, Iizawa Y.
    Antimicrob Agents Chemother; 2005 Nov 01; 49(11):4584-91. PubMed ID: 16251299
    [Abstract] [Full Text] [Related]

  • 8. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
    Navenot JM, Wang ZX, Trent JO, Murray JL, Hu QX, DeLeeuw L, Moore PS, Chang Y, Peiper SC.
    J Mol Biol; 2001 Nov 09; 313(5):1181-93. PubMed ID: 11700073
    [Abstract] [Full Text] [Related]

  • 9. Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7.
    Aarons EJ, Beddows S, Willingham T, Wu L, Koup RA.
    Virology; 2001 Sep 01; 287(2):382-90. PubMed ID: 11531415
    [Abstract] [Full Text] [Related]

  • 10. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies.
    Blanpain C, Vanderwinden JM, Cihak J, Wittamer V, Le Poul E, Issafras H, Stangassinger M, Vassart G, Marullo S, Schlndorff D, Parmentier M, Mack M.
    Mol Biol Cell; 2002 Feb 01; 13(2):723-37. PubMed ID: 11854425
    [Abstract] [Full Text] [Related]

  • 11. Selection of active ScFv to G-protein-coupled receptor CCR5 using surface antigen-mimicking peptides.
    Zhang Y, Pool C, Sadler K, Yan HP, Edl J, Wang X, Boyd JG, Tam JP.
    Biochemistry; 2004 Oct 05; 43(39):12575-84. PubMed ID: 15449947
    [Abstract] [Full Text] [Related]

  • 12. A new prospective against HIV infection: induction of murin CCR5-downregulating antibodies.
    Barassi C, Marenzi C, Pastori C, Longhi R, Lazzarin A, Lopalco L.
    New Microbiol; 2004 Apr 05; 27(2 Suppl 1):85-94. PubMed ID: 15646069
    [Abstract] [Full Text] [Related]

  • 13. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism.
    Blanco J, Barretina J, Clotet B, Esté JA.
    J Leukoc Biol; 2004 Oct 05; 76(4):804-11. PubMed ID: 15258189
    [Abstract] [Full Text] [Related]

  • 14. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, Koyanagi Y, Mitsuya H.
    J Virol; 2004 Aug 05; 78(16):8654-62. PubMed ID: 15280474
    [Abstract] [Full Text] [Related]

  • 15. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
    Takashima K, Miyake H, Furuta RA, Fujisawa JI, Iizawa Y, Kanzaki N, Shiraishi M, Okonogi K, Baba M.
    Antimicrob Agents Chemother; 2001 Dec 05; 45(12):3538-43. PubMed ID: 11709336
    [Abstract] [Full Text] [Related]

  • 16. Alterations in mast cell function and survival following in vitro infection with human immunodeficiency viruses-1 through CXCR4.
    Taub DD, Mikovits JA, Nilsson G, Schaffer EM, Key ML, Petrow-Sadowski C, Ruscetti FW.
    Cell Immunol; 2004 Aug 05; 230(2):65-80. PubMed ID: 15598422
    [Abstract] [Full Text] [Related]

  • 17. Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization.
    Szabo I, Wetzel MA, Zhang N, Steele AD, Kaminsky DE, Chen C, Liu-Chen LY, Bednar F, Henderson EE, Howard OM, Oppenheim JJ, Rogers TJ.
    J Leukoc Biol; 2003 Dec 05; 74(6):1074-82. PubMed ID: 12972507
    [Abstract] [Full Text] [Related]

  • 18. Soluble chemokine CCR5 receptor is present in human plasma.
    Tsimanis A, Kalinkovich A, Bentwich Z.
    Immunol Lett; 2005 Jan 15; 96(1):55-61. PubMed ID: 15585308
    [Abstract] [Full Text] [Related]

  • 19. Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5.
    Cordelier P, Kulkowsky JW, Ko C, Matskevitch AA, McKee HJ, Rossi JJ, Bouhamdan M, Pomerantz RJ, Kari G, Strayer DS.
    Gene Ther; 2004 Nov 15; 11(22):1627-37. PubMed ID: 15295615
    [Abstract] [Full Text] [Related]

  • 20. IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes.
    Losana G, Bovolenta C, Rigamonti L, Borghi I, Altare F, Jouanguy E, Forni G, Casanova JL, Sherry B, Mengozzi M, Trinchieri G, Poli G, Gerosa F, Novelli F.
    J Leukoc Biol; 2002 Oct 15; 72(4):735-42. PubMed ID: 12377943
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.